Specialised Therapeutics Alim Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
2 result(s) found, displaying 1 to 2
-
Australian Public Assessment Report (AusPAR)Minjuvi (tafasitamab) is provisionally approved for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplants.
-
Australian Public Assessment Report (AusPAR)AusPAR for Pemazyre (pemigatinib) for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that has progressed after at least one prior line of systemic therapy.